NO333525B1 - Preparat for transdermal levering av fentanyl - Google Patents
Preparat for transdermal levering av fentanyl Download PDFInfo
- Publication number
- NO333525B1 NO333525B1 NO20031165A NO20031165A NO333525B1 NO 333525 B1 NO333525 B1 NO 333525B1 NO 20031165 A NO20031165 A NO 20031165A NO 20031165 A NO20031165 A NO 20031165A NO 333525 B1 NO333525 B1 NO 333525B1
- Authority
- NO
- Norway
- Prior art keywords
- fentanyl
- copolymer
- preparation
- preparation according
- coated
- Prior art date
Links
- 229960002428 fentanyl Drugs 0.000 title claims abstract description 141
- 238000002360 preparation method Methods 0.000 title claims abstract description 90
- 230000037317 transdermal delivery Effects 0.000 title claims description 21
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 title abstract description 5
- 229920001577 copolymer Polymers 0.000 claims abstract description 113
- 239000000203 mixture Substances 0.000 claims abstract description 30
- 238000013271 transdermal drug delivery Methods 0.000 claims abstract description 27
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 claims description 140
- 239000010410 layer Substances 0.000 claims description 60
- DXPPIEDUBFUSEZ-UHFFFAOYSA-N 6-methylheptyl prop-2-enoate Chemical group CC(C)CCCCCOC(=O)C=C DXPPIEDUBFUSEZ-UHFFFAOYSA-N 0.000 claims description 45
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical group OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 claims description 37
- 239000002671 adjuvant Substances 0.000 claims description 34
- 239000003814 drug Substances 0.000 claims description 31
- 229940079593 drug Drugs 0.000 claims description 30
- 239000000178 monomer Substances 0.000 claims description 25
- -1 alkyl methacrylates Chemical class 0.000 claims description 24
- 239000012528 membrane Substances 0.000 claims description 23
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims description 17
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 239000004926 polymethyl methacrylate Substances 0.000 claims description 10
- 241000124008 Mammalia Species 0.000 claims description 9
- 210000002966 serum Anatomy 0.000 claims description 9
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 8
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 5
- 229930195729 fatty acid Natural products 0.000 claims description 5
- 239000000194 fatty acid Substances 0.000 claims description 5
- 125000005250 alkyl acrylate group Chemical group 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- GOXQRTZXKQZDDN-UHFFFAOYSA-N 2-Ethylhexyl acrylate Chemical compound CCCCC(CC)COC(=O)C=C GOXQRTZXKQZDDN-UHFFFAOYSA-N 0.000 claims description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 2
- CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 claims description 2
- 239000004202 carbamide Substances 0.000 claims description 2
- 150000003857 carboxamides Chemical class 0.000 claims description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- KBLWLMPSVYBVDK-UHFFFAOYSA-N cyclohexyl prop-2-enoate Chemical compound C=CC(=O)OC1CCCCC1 KBLWLMPSVYBVDK-UHFFFAOYSA-N 0.000 claims description 2
- 150000002191 fatty alcohols Chemical class 0.000 claims description 2
- 125000000524 functional group Chemical group 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000037307 sensitive skin Effects 0.000 claims description 2
- 229940124530 sulfonamide Drugs 0.000 claims description 2
- 150000003456 sulfonamides Chemical class 0.000 claims description 2
- 150000003505 terpenes Chemical class 0.000 claims description 2
- 235000007586 terpenes Nutrition 0.000 claims description 2
- 230000036592 analgesia Effects 0.000 claims 2
- 125000006313 (C5-C8) alkyl group Chemical group 0.000 claims 1
- OWPUOLBODXJOKH-UHFFFAOYSA-N 2,3-dihydroxypropyl prop-2-enoate Chemical compound OCC(O)COC(=O)C=C OWPUOLBODXJOKH-UHFFFAOYSA-N 0.000 claims 1
- 239000004821 Contact adhesive Substances 0.000 claims 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 claims 1
- OVHHHVAVHBHXAK-UHFFFAOYSA-N n,n-diethylprop-2-enamide Chemical compound CCN(CC)C(=O)C=C OVHHHVAVHBHXAK-UHFFFAOYSA-N 0.000 claims 1
- 229920005862 polyol Polymers 0.000 claims 1
- UQDUPQYQJKYHQI-UHFFFAOYSA-N methyl laurate Chemical compound CCCCCCCCCCCC(=O)OC UQDUPQYQJKYHQI-UHFFFAOYSA-N 0.000 abstract description 60
- UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical compound OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 abstract description 18
- 238000012384 transportation and delivery Methods 0.000 abstract description 13
- 239000003961 penetration enhancing agent Substances 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 102
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 84
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 36
- 239000000243 solution Substances 0.000 description 35
- 238000010998 test method Methods 0.000 description 35
- 238000000576 coating method Methods 0.000 description 33
- 239000011248 coating agent Substances 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- 230000035515 penetration Effects 0.000 description 26
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 24
- 229920001296 polysiloxane Polymers 0.000 description 24
- 229920006267 polyester film Polymers 0.000 description 21
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 18
- 239000008199 coating composition Substances 0.000 description 18
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 229920000642 polymer Polymers 0.000 description 13
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- AVTLBBWTUPQRAY-UHFFFAOYSA-N 2-(2-cyanobutan-2-yldiazenyl)-2-methylbutanenitrile Chemical compound CCC(C)(C#N)N=NC(C)(CC)C#N AVTLBBWTUPQRAY-UHFFFAOYSA-N 0.000 description 11
- 239000011521 glass Substances 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- SYELZBGXAIXKHU-UHFFFAOYSA-N dodecyldimethylamine N-oxide Chemical compound CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 238000009472 formulation Methods 0.000 description 8
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 8
- 229920006397 acrylic thermoplastic Polymers 0.000 description 7
- 239000000853 adhesive Substances 0.000 description 7
- 230000001070 adhesive effect Effects 0.000 description 7
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 7
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 230000002708 enhancing effect Effects 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 5
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 5
- 238000009792 diffusion process Methods 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- 229920002367 Polyisobutene Polymers 0.000 description 4
- 230000003444 anaesthetic effect Effects 0.000 description 4
- 235000001510 limonene Nutrition 0.000 description 4
- 229940087305 limonene Drugs 0.000 description 4
- 229940041616 menthol Drugs 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 3
- 239000005977 Ethylene Substances 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 3
- 239000012790 adhesive layer Substances 0.000 description 3
- WUOACPNHFRMFPN-UHFFFAOYSA-N alpha-terpineol Chemical compound CC1=CCC(C(C)(C)O)CC1 WUOACPNHFRMFPN-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- SQIFACVGCPWBQZ-UHFFFAOYSA-N delta-terpineol Natural products CC(C)(O)C1CCC(=C)CC1 SQIFACVGCPWBQZ-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229960004207 fentanyl citrate Drugs 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 229920003052 natural elastomer Polymers 0.000 description 3
- 229920001194 natural rubber Polymers 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 229920003051 synthetic elastomer Polymers 0.000 description 3
- 239000005061 synthetic rubber Substances 0.000 description 3
- 229940116411 terpineol Drugs 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- LPEKGGXMPWTOCB-UHFFFAOYSA-N 8beta-(2,3-epoxy-2-methylbutyryloxy)-14-acetoxytithifolin Natural products COC(=O)C(C)O LPEKGGXMPWTOCB-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 2
- 229920001824 Barex® Polymers 0.000 description 2
- BAVONGHXFVOKBV-UHFFFAOYSA-N Carveol Chemical compound CC(=C)C1CC=C(C)C(O)C1 BAVONGHXFVOKBV-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- 244000043261 Hevea brasiliensis Species 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- ULDHMXUKGWMISQ-UHFFFAOYSA-N carvone Chemical compound CC(=C)C1CC=C(C)C(=O)C1 ULDHMXUKGWMISQ-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000011505 plaster Substances 0.000 description 2
- 229920001195 polyisoprene Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 2
- 229920005573 silicon-containing polymer Polymers 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 229920006132 styrene block copolymer Polymers 0.000 description 2
- 238000010345 tape casting Methods 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 description 1
- NZGWDASTMWDZIW-MRVPVSSYSA-N (+)-pulegone Chemical compound C[C@@H]1CCC(=C(C)C)C(=O)C1 NZGWDASTMWDZIW-MRVPVSSYSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- BAVONGHXFVOKBV-ZJUUUORDSA-N (-)-trans-carveol Natural products CC(=C)[C@@H]1CC=C(C)[C@@H](O)C1 BAVONGHXFVOKBV-ZJUUUORDSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- JWYVGKFDLWWQJX-UHFFFAOYSA-N 1-ethenylazepan-2-one Chemical compound C=CN1CCCCCC1=O JWYVGKFDLWWQJX-UHFFFAOYSA-N 0.000 description 1
- PBGPBHYPCGDFEZ-UHFFFAOYSA-N 1-ethenylpiperidin-2-one Chemical compound C=CN1CCCCC1=O PBGPBHYPCGDFEZ-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- SBASXUCJHJRPEV-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethanol Chemical compound COCCOCCO SBASXUCJHJRPEV-UHFFFAOYSA-N 0.000 description 1
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- WYGWHHGCAGTUCH-UHFFFAOYSA-N 2-[(2-cyano-4-methylpentan-2-yl)diazenyl]-2,4-dimethylpentanenitrile Chemical compound CC(C)CC(C)(C#N)N=NC(C)(C#N)CC(C)C WYGWHHGCAGTUCH-UHFFFAOYSA-N 0.000 description 1
- VHSHLMUCYSAUQU-UHFFFAOYSA-N 2-hydroxypropyl methacrylate Chemical compound CC(O)COC(=O)C(C)=C VHSHLMUCYSAUQU-UHFFFAOYSA-N 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- YSTPAHQEHQSRJD-UHFFFAOYSA-N 3-Carvomenthenone Chemical compound CC(C)C1CCC(C)=CC1=O YSTPAHQEHQSRJD-UHFFFAOYSA-N 0.000 description 1
- WRYLYDPHFGVWKC-SNVBAGLBSA-N 4-Terpineol Natural products CC(C)[C@]1(O)CCC(C)=CC1 WRYLYDPHFGVWKC-SNVBAGLBSA-N 0.000 description 1
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000000003 Breakthrough pain Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000005973 Carvone Substances 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical class COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- GYCMBHHDWRMZGG-UHFFFAOYSA-N Methylacrylonitrile Chemical compound CC(=C)C#N GYCMBHHDWRMZGG-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- NZGWDASTMWDZIW-UHFFFAOYSA-N Pulegone Natural products CC1CCC(=C(C)C)C(=O)C1 NZGWDASTMWDZIW-UHFFFAOYSA-N 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- LCXXNKZQVOXMEH-UHFFFAOYSA-N Tetrahydrofurfuryl methacrylate Chemical compound CC(=C)C(=O)OCC1CCCO1 LCXXNKZQVOXMEH-UHFFFAOYSA-N 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000001346 alkyl aryl ethers Chemical class 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- USMNOWBWPHYOEA-UHFFFAOYSA-N alpha-thujone Natural products CC1C(=O)CC2(C(C)C)C1C2 USMNOWBWPHYOEA-UHFFFAOYSA-N 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 229930007646 carveol Natural products 0.000 description 1
- KMPWYEUPVWOPIM-UHFFFAOYSA-N cinchonidine Natural products C1=CC=C2C(C(C3N4CCC(C(C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-UHFFFAOYSA-N 0.000 description 1
- 229930007050 cineol Natural products 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- RBNWAMSGVWEHFP-UHFFFAOYSA-N cis-p-Menthan-1,8-diol Natural products CC(C)(O)C1CCC(C)(O)CC1 RBNWAMSGVWEHFP-UHFFFAOYSA-N 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 231100000313 clinical toxicology Toxicity 0.000 description 1
- FCSHDIVRCWTZOX-DVTGEIKXSA-N clobetasol Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O FCSHDIVRCWTZOX-DVTGEIKXSA-N 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 229940031578 diisopropyl adipate Drugs 0.000 description 1
- 150000005218 dimethyl ethers Chemical class 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 229940099191 duragesic Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- DOMLXBPXLNDFAB-UHFFFAOYSA-N ethoxyethane;methyl prop-2-enoate Chemical compound CCOCC.COC(=O)C=C DOMLXBPXLNDFAB-UHFFFAOYSA-N 0.000 description 1
- WZXNKIQZEIEZEA-UHFFFAOYSA-N ethyl 2-(2-ethoxyethoxy)prop-2-enoate Chemical compound CCOCCOC(=C)C(=O)OCC WZXNKIQZEIEZEA-UHFFFAOYSA-N 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000007765 extrusion coating Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000004811 fluoropolymer Substances 0.000 description 1
- 229920002313 fluoropolymer Polymers 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- DWXAVNJYFLGAEF-UHFFFAOYSA-N furan-2-ylmethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC1=CC=CO1 DWXAVNJYFLGAEF-UHFFFAOYSA-N 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- 229940068939 glyceryl monolaurate Drugs 0.000 description 1
- VOZRXNHHFUQHIL-UHFFFAOYSA-N glycidyl methacrylate Chemical compound CC(=C)C(=O)OCC1CO1 VOZRXNHHFUQHIL-UHFFFAOYSA-N 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229930002839 ionone Natural products 0.000 description 1
- 150000002499 ionone derivatives Chemical class 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229920000092 linear low density polyethylene Polymers 0.000 description 1
- 239000004707 linear low-density polyethylene Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229930007503 menthone Natural products 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 1
- 229940057867 methyl lactate Drugs 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PNLUGRYDUHRLOF-UHFFFAOYSA-N n-ethenyl-n-methylacetamide Chemical compound C=CN(C)C(C)=O PNLUGRYDUHRLOF-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 229930007459 p-menth-8-en-3-one Natural products 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 239000011101 paper laminate Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229930006968 piperitone Natural products 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 239000002964 rayon Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- MUTNCGKQJGXKEM-UHFFFAOYSA-N tamibarotene Chemical compound C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1NC(=O)C1=CC=C(C(O)=O)C=C1 MUTNCGKQJGXKEM-UHFFFAOYSA-N 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Macromonomer-Based Addition Polymer (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23697300P | 2000-09-29 | 2000-09-29 | |
| US28401701P | 2001-04-16 | 2001-04-16 | |
| PCT/US2001/031052 WO2002026217A2 (en) | 2000-09-29 | 2001-09-27 | Composition for the transdermal delivery of fentanyl |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20031165D0 NO20031165D0 (no) | 2003-03-13 |
| NO20031165L NO20031165L (no) | 2003-05-26 |
| NO333525B1 true NO333525B1 (no) | 2013-07-01 |
Family
ID=26930280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20031165A NO333525B1 (no) | 2000-09-29 | 2003-03-13 | Preparat for transdermal levering av fentanyl |
Country Status (24)
| Country | Link |
|---|---|
| US (18) | US20020119187A1 (de) |
| EP (6) | EP2158905B1 (de) |
| JP (6) | JP2004513890A (de) |
| KR (1) | KR20030043978A (de) |
| CN (1) | CN100490805C (de) |
| AR (1) | AR037081A1 (de) |
| AT (1) | ATE449599T1 (de) |
| AU (2) | AU2002215315C1 (de) |
| BR (1) | BR0114315A (de) |
| CA (1) | CA2423836C (de) |
| CY (1) | CY1118798T1 (de) |
| CZ (1) | CZ305119B6 (de) |
| DE (1) | DE60140616D1 (de) |
| DK (2) | DK2153828T3 (de) |
| EE (1) | EE05391B1 (de) |
| ES (2) | ES2407987T3 (de) |
| HU (1) | HUP0302926A3 (de) |
| IL (1) | IL154857A0 (de) |
| MX (1) | MXPA03002548A (de) |
| NO (1) | NO333525B1 (de) |
| NZ (1) | NZ524767A (de) |
| PL (1) | PL360708A1 (de) |
| PT (2) | PT2158905E (de) |
| WO (1) | WO2002026217A2 (de) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19814084B4 (de) * | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung |
| US9056060B2 (en) * | 2000-09-19 | 2015-06-16 | Henkel Ag & Co. Kgaa | Non-reactive adhesive useful in transdermal drug delivery system |
| US20020119187A1 (en) * | 2000-09-29 | 2002-08-29 | Cantor Adam S. | Composition for the transdermal delivery of fentanyl |
| DK1381352T3 (da) * | 2001-03-16 | 2007-07-09 | Alza Corp | Plaster til transdermal indgivelse af fentanyl |
| DE20221247U1 (de) * | 2001-03-16 | 2005-09-15 | Alza Corp | Transdermal-Pflaster zum Verabreichen von Fentanyl |
| US20050208117A1 (en) * | 2001-03-16 | 2005-09-22 | Venkatraman Subramanian S | Transdermal administration of fentanyl and analogs thereof |
| DE10141650C1 (de) * | 2001-08-24 | 2002-11-28 | Lohmann Therapie Syst Lts | Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen |
| AU2007202273B2 (en) * | 2001-08-24 | 2009-11-05 | Lts Lohmann Therapie - Systeme Ag | Transdermal therapeutic system containing fentanyl or related substance |
| CA2496454A1 (en) | 2002-04-23 | 2003-11-06 | Alza Corporation | Transdermal analgesic systems with reduced abuse potential |
| AR033748A1 (es) | 2002-05-15 | 2004-01-07 | Thalas Group Inc | Un dispositivo para la administracion transdermica de sustancias farmacologicamente activas que comprende dos capas adhesivas superpuestas y un procedimiento para prepararlo |
| CN1655772B (zh) * | 2002-05-28 | 2010-05-26 | 拉伯泰克技术研发有限公司 | 含有芬太尼的贴剂 |
| DE10223835A1 (de) * | 2002-05-28 | 2003-12-11 | Labtec Gmbh | Pflaster, enthaltend Fentanylum |
| US8246980B2 (en) * | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system |
| DE10234673B4 (de) * | 2002-07-30 | 2007-08-16 | Schwarz Pharma Ag | Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren |
| EP1386604A1 (de) * | 2002-07-30 | 2004-02-04 | Schwarz Pharma Ag | Verbessertes transdermales Verabreichungssystem |
| US8246979B2 (en) | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system for the administration of rotigotine |
| US8211462B2 (en) * | 2002-07-30 | 2012-07-03 | Ucb Pharma Gmbh | Hot-melt TTS for administering rotigotine |
| US20040086551A1 (en) * | 2002-10-30 | 2004-05-06 | Miller Kenneth J. | Fentanyl suspension-based silicone adhesive formulations and devices for transdermal delivery of fentanyl |
| PT1426049E (pt) * | 2002-12-02 | 2005-09-30 | Sanol Arznei Schwarz Gmbh | Administracao iontoforetica de rotigotina para o tratamento da doenca de parkinson |
| DE10261696A1 (de) | 2002-12-30 | 2004-07-15 | Schwarz Pharma Ag | Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base |
| US20040219195A1 (en) * | 2003-04-30 | 2004-11-04 | 3M Innovative Properties Company | Abuse-resistant transdermal dosage form |
| US8790689B2 (en) | 2003-04-30 | 2014-07-29 | Purdue Pharma L.P. | Tamper resistant transdermal dosage form |
| US7182955B2 (en) * | 2003-04-30 | 2007-02-27 | 3M Innovative Properties Company | Abuse-resistant transdermal dosage form |
| CL2004000927A1 (es) | 2003-04-30 | 2005-01-28 | Purdue Pharma Lp | Forma de dosificacion transdermica que comprende un agente activo, una superficie proxima y una superficie distal. |
| CA2546200A1 (en) * | 2003-11-18 | 2005-06-02 | 3M Innovative Properties Company | Olanzapine containing transdermal drug delivery compositions |
| US20050202073A1 (en) † | 2004-03-09 | 2005-09-15 | Mylan Technologies, Inc. | Transdermal systems containing multilayer adhesive matrices to modify drug delivery |
| US9205062B2 (en) | 2004-03-09 | 2015-12-08 | Mylan Pharmaceuticals, Inc. | Transdermal systems containing multilayer adhesive matrices to modify drug delivery |
| JP2007532645A (ja) * | 2004-04-13 | 2007-11-15 | アルザ コーポレイション | フェンタニルに基づく薬剤の経皮送達システム用の器具および方法 |
| KR20070053267A (ko) * | 2004-08-20 | 2007-05-23 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | 반투명 보호 필름을 갖는 경피 약물 전달 장치 |
| US8252320B2 (en) | 2004-10-21 | 2012-08-28 | Durect Corporation | Transdermal delivery system for sufentanil |
| CA2583642C (en) | 2004-10-21 | 2013-06-25 | Durect Corporation | Transdermal delivery systems |
| CA2611224C (en) * | 2005-06-10 | 2014-01-21 | 3M Innovative Properties Company | Method for handling adhesive laminate sections |
| EP1948142B1 (de) | 2005-09-23 | 2014-04-09 | ALZA Corporation | Polyacrylatformulierung mit hoher beladung von verstärkenden substanzen für transdermale anwendungen |
| EP1937226A2 (de) * | 2005-09-23 | 2008-07-02 | Alza Corporation | Transdermales galantaminzufuhrsystem |
| US20070098772A1 (en) * | 2005-09-23 | 2007-05-03 | Westcott Tyler D | Transdermal norelgestromin delivery system |
| JP5114042B2 (ja) * | 2005-10-19 | 2013-01-09 | ニプロパッチ株式会社 | 貼付剤、及び貼付剤の製造方法 |
| US7888422B2 (en) | 2005-11-09 | 2011-02-15 | Mylan Technologies Inc. | Long-wearing removable pressure sensitive adhesive |
| GB0615136D0 (en) * | 2006-07-29 | 2006-09-06 | Univ Edinburgh | Induction of analgesia in neuropathic pain |
| JP5227041B2 (ja) * | 2007-02-28 | 2013-07-03 | 日東電工株式会社 | 薬物含有貼付製剤 |
| CN100465201C (zh) * | 2007-04-25 | 2009-03-04 | 上海大学 | 用作药物肠溶包衣材料的水溶性丙烯酸系树脂乳液的制备方法 |
| US9017301B2 (en) * | 2007-09-04 | 2015-04-28 | Mylan Technologies, Inc. | Transdermal drug delivery systems comprising a coated release liner |
| MY188123A (en) | 2007-10-15 | 2021-11-22 | Alza Corp | Once-a-day replacement transdermal administration of fentanyl |
| CA2711774C (en) | 2008-01-28 | 2016-05-24 | Teikoku Seiyaku Co., Ltd. | Fentanyl-containing patch for external use |
| KR20090101579A (ko) * | 2008-03-24 | 2009-09-29 | 조선대학교산학협력단 | 펜타닐을 함유한 경피 흡수제 |
| DE102009052972A1 (de) | 2009-11-12 | 2011-09-15 | Lts Lohmann Therapie-Systeme Ag | Verfahren zur Verhinderung der Kristallisation von Arzneistoffen in einem Polymerfilm |
| CA2806183C (en) * | 2010-07-21 | 2019-01-08 | 3M Innovative Properties Company | Transdermal adhesive compositions, devices, and methods |
| CN103930098B (zh) * | 2011-09-22 | 2017-06-06 | 株式会社三养生物制药 | 含有芬太尼及其同族体的经皮吸收制剂 |
| EP3936133A1 (de) | 2011-11-23 | 2022-01-12 | TherapeuticsMD, Inc. | Natürliche kombinationshormonersatzformulierungen und therapien |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| EP2712612B1 (de) * | 2012-09-28 | 2020-03-25 | Nitto Denko Corporation | Pflasterpräparat mir Aminoxid und Isopropylmyristat |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| AU2015264003A1 (en) | 2014-05-22 | 2016-11-17 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| KR20170045225A (ko) * | 2014-08-25 | 2017-04-26 | 헨켈 아이피 앤드 홀딩 게엠베하 | 아크릴 중합체 및 그의 경피 약물 전달에서의 용도 |
| JP6940407B2 (ja) * | 2014-12-19 | 2021-09-29 | キンデーバ ドラッグ デリバリー リミティド パートナーシップ | フェンタニルを含む経皮薬物送達デバイス |
| US10010543B1 (en) | 2014-12-23 | 2018-07-03 | Barr Laboratories, Inc. | Transdermal dosage form |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| US10318810B2 (en) * | 2015-09-18 | 2019-06-11 | SlantRange, Inc. | Systems and methods for determining statistics plant populations based on overhead optical measurements |
| BR112018070199A2 (pt) | 2016-04-01 | 2019-01-29 | Therapeuticsmd Inc | composição farmacêutica de hormônio esteroide |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| JP6500982B2 (ja) * | 2016-05-19 | 2019-04-17 | 三菱ケミカル株式会社 | マクロモノマー共重合体およびその製造方法 |
| JPWO2019022249A1 (ja) * | 2017-07-28 | 2020-07-09 | 国立大学法人九州大学 | ミノキシジルの放出が制御された経皮吸収組成物 |
| EP3700511A1 (de) | 2017-10-17 | 2020-09-02 | Lubrizol Advanced Materials, Inc. | Zusammensetzung und vorrichtung zur wirkstoffabgabe an hautflächen |
| CA3095873A1 (en) * | 2018-04-05 | 2019-10-10 | Steven Robert ERBST | Therapeutic elastic bandage for modulating the endocannabinoid system |
| WO2020009685A1 (en) | 2018-07-02 | 2020-01-09 | John Tang | Transdermal dosage form |
| WO2020008366A1 (en) | 2018-07-02 | 2020-01-09 | Clexio Biosciences Ltd. | Transdermal dosage form |
| MX2022000274A (es) * | 2019-07-11 | 2022-02-03 | Henkel Ag & Co Kgaa | Polimero acrilico y composiciones adhesivas. |
| DE102019120403A1 (de) | 2019-07-29 | 2021-02-04 | Lts Lohmann Therapie-Systeme Ag | Verfahren zur Herstellung von Haftklebemassen zur Verwendung in einem transdermalen therapeutischen System |
| CN111471126A (zh) * | 2020-03-23 | 2020-07-31 | 杭州鹿扬科技有限公司 | 皮肤用粘贴材料及其制备方法 |
| US11964121B2 (en) | 2021-10-13 | 2024-04-23 | Satio, Inc. | Mono dose dermal patch for pharmaceutical delivery |
| US12029562B2 (en) | 2021-04-14 | 2024-07-09 | Satio, Inc. | Dermal patch system |
| US12053284B2 (en) | 2021-11-08 | 2024-08-06 | Satio, Inc. | Dermal patch for collecting a physiological sample |
| US11877848B2 (en) | 2021-11-08 | 2024-01-23 | Satio, Inc. | Dermal patch for collecting a physiological sample |
| US12048543B2 (en) | 2021-11-08 | 2024-07-30 | Satio, Inc. | Dermal patch for collecting a physiological sample with removable vial |
| US12023156B2 (en) | 2021-10-13 | 2024-07-02 | Satio, Inc. | Dermal patch for collecting a physiological sample |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996008229A2 (en) * | 1994-09-14 | 1996-03-21 | Minnesota Mining And Manufacturing Company | Matrix for transdermal drug delivery |
Family Cites Families (109)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE24906E (en) | 1955-11-18 | 1960-12-13 | Pressure-sensitive adhesive sheet material | |
| US3352708A (en) * | 1964-03-02 | 1967-11-14 | Ball Brothers Co Inc | Glass having dual protective coatings thereon and method for forming such coatings |
| US3886126A (en) * | 1973-04-09 | 1975-05-27 | Monsanto Co | Solutions of pressure-sensitive resin solutions with improved viscosity and flow |
| US3900610A (en) * | 1973-04-09 | 1975-08-19 | Monsanto Co | Process of making a pressure sensitive adhesive article |
| US4405616A (en) * | 1975-06-19 | 1983-09-20 | Nelson Research & Development Company | Penetration enhancers for transdermal drug delivery of systemic agents |
| US4291015A (en) * | 1979-08-14 | 1981-09-22 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix containing a vasodilator |
| US4314557A (en) * | 1980-05-19 | 1982-02-09 | Alza Corporation | Dissolution controlled active agent dispenser |
| US4379454A (en) * | 1981-02-17 | 1983-04-12 | Alza Corporation | Dosage for coadministering drug and percutaneous absorption enhancer |
| US4460372A (en) * | 1981-02-17 | 1984-07-17 | Alza Corporation | Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer |
| US4435180A (en) * | 1982-05-25 | 1984-03-06 | Alza Corporation | Elastomeric active agent delivery system and method of use |
| US5310559A (en) * | 1982-09-01 | 1994-05-10 | Hercon Laboratories Corporation | Device for controlled release and delivery to mammalian tissue of pharmacologically active agents incorporating a rate controlling member which comprises an alkylene-alkyl acrylate copolymer |
| US4704282A (en) * | 1984-06-29 | 1987-11-03 | Alza Corporation | Transdermal therapeutic system having improved delivery characteristics |
| US4725439A (en) * | 1984-06-29 | 1988-02-16 | Alza Corporation | Transdermal drug delivery device |
| US4588580B2 (en) * | 1984-07-23 | 1999-02-16 | Alaz Corp | Transdermal administration of fentanyl and device therefor |
| US4626539A (en) * | 1984-08-10 | 1986-12-02 | E. I. Dupont De Nemours And Company | Trandermal delivery of opioids |
| US4568343A (en) * | 1984-10-09 | 1986-02-04 | Alza Corporation | Skin permeation enhancer compositions |
| US4655767A (en) * | 1984-10-29 | 1987-04-07 | Dow Corning Corporation | Transdermal drug delivery devices with amine-resistant silicone adhesives |
| US4645502A (en) * | 1985-05-03 | 1987-02-24 | Alza Corporation | Transdermal delivery of highly ionized fat insoluble drugs |
| US4693776A (en) | 1985-05-16 | 1987-09-15 | Minnesota Mining And Manufacturing Company | Macromer reinforced pressure sensitive skin adhesive |
| US4698062A (en) * | 1985-10-30 | 1987-10-06 | Alza Corporation | Medical device for pulsatile transdermal delivery of biologically active agents |
| US4732808A (en) | 1985-11-14 | 1988-03-22 | Minnesota Mining And Manufacturing Company | Macromer reinforced pressure sensitive skin adhesive sheet material |
| US4954343A (en) * | 1986-03-29 | 1990-09-04 | Nitto Electric Industrial Co., Ltd. | Dermal pharmaceutical preparations |
| US5560922A (en) * | 1986-05-30 | 1996-10-01 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit using a polyacrylate adhesive polymer and process |
| US5820876A (en) * | 1986-08-28 | 1998-10-13 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Transdermal therapeutic system |
| US4938759A (en) * | 1986-09-02 | 1990-07-03 | Alza Corporation | Transdermal delivery device having a rate controlling adhesive |
| US5344656A (en) * | 1986-09-12 | 1994-09-06 | Alza Corporation | Subsaturated transdermal therapeutic system having improved release characteristics |
| US4908027A (en) * | 1986-09-12 | 1990-03-13 | Alza Corporation | Subsaturated transdermal therapeutic system having improved release characteristics |
| US4917676A (en) * | 1986-11-20 | 1990-04-17 | Ciba-Geigy Corporation | User-activated transdermal therapeutic system |
| AU601528B2 (en) * | 1986-12-22 | 1990-09-13 | Ortho-Mcneil Pharmaceutical, Inc. | Resilient transdermal drug-delivery device and compositions and devices employing fatty acid esters/ethers of alkanediols and percutaneous absorption enhancers |
| US5006342A (en) * | 1986-12-22 | 1991-04-09 | Cygnus Corporation | Resilient transdermal drug delivery device |
| AU607172B2 (en) * | 1986-12-22 | 1991-02-28 | Cygnus, Inc. | Diffusion matrix for transdermal drug administration |
| US4906463A (en) * | 1986-12-22 | 1990-03-06 | Cygnus Research Corporation | Transdermal drug-delivery composition |
| US4876249A (en) * | 1987-01-12 | 1989-10-24 | Rajadhyaksha Vithal J | Compositions and method comprising heterocyclic compounds containing two heteroatoms |
| US4911707A (en) * | 1987-02-13 | 1990-03-27 | Ciba-Geigy Corporation | Monolithic user-activated transdermal therapeutic system |
| US4822802A (en) * | 1987-02-24 | 1989-04-18 | Alza Corporation | Method of fentanly administration for postoperative pain relief |
| US4865848A (en) * | 1987-02-26 | 1989-09-12 | Alza Corporation | Skin permeation enhancer compositions using sucrose esters |
| US4900555A (en) * | 1987-02-26 | 1990-02-13 | Alza Corporation | Skin permeation enhancer compositions using sucrose esters |
| US4940586A (en) * | 1987-02-26 | 1990-07-10 | Alza Corporation | Skin permeation enhancer compositions using sucrose esters |
| US5186939A (en) * | 1987-04-23 | 1993-02-16 | Cygnus Therapeutic Systems | Laminated composite for transdermal administration of fentanyl |
| US4879297A (en) * | 1987-06-01 | 1989-11-07 | Warner-Lambert Company | Fatty acids and their small chain esters as penetration enhancers in aqueous systems |
| DE3729299A1 (de) * | 1987-09-02 | 1989-03-23 | Beiersdorf Ag | Transdermales therapeutisches system |
| US4837027A (en) * | 1987-11-09 | 1989-06-06 | Alza Corporation | Transdermal drug delivery device |
| US4781924A (en) * | 1987-11-09 | 1988-11-01 | Alza Corporation | Transdermal drug delivery device |
| GB8804164D0 (en) * | 1988-02-23 | 1988-03-23 | Tucker J M | Bandage for administering physiologically active compound |
| US4994267A (en) | 1988-03-04 | 1991-02-19 | Noven Pharmaceuticals, Inc. | Transdermal acrylic multipolymer drug delivery system |
| US5656286A (en) | 1988-03-04 | 1997-08-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
| US5300291A (en) * | 1988-03-04 | 1994-04-05 | Noven Pharmaceuticals, Inc. | Method and device for the release of drugs to the skin |
| US5474783A (en) * | 1988-03-04 | 1995-12-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
| US5364630A (en) * | 1988-06-14 | 1994-11-15 | Alza Corporation | Subsaturated nicotine transdermal therapeutic system |
| US5004610A (en) * | 1988-06-14 | 1991-04-02 | Alza Corporation | Subsaturated nicotine transdermal therapeutic system |
| US5236714A (en) * | 1988-11-01 | 1993-08-17 | Alza Corporation | Abusable substance dosage form having reduced abuse potential |
| US5223262A (en) * | 1989-02-23 | 1993-06-29 | University Of Utah | Transdermal delivery system utilizing one way membranes |
| US5162315A (en) * | 1989-05-08 | 1992-11-10 | Rajadhyaksha Vithal J | Penetration enhancers |
| WO1991003219A1 (en) * | 1989-09-08 | 1991-03-21 | Cygnus Research Corporation | Solid matrix system for transdermal drug delivery |
| JP3046346B2 (ja) * | 1990-03-12 | 2000-05-29 | 昭和電工株式会社 | 外用剤基剤又は補助剤とそれを含有する人又は動物の外用剤 |
| US5069909A (en) * | 1990-06-20 | 1991-12-03 | Cygnus Therapeutic Systems | Transdermal administration of buprenorphine |
| US5152997A (en) * | 1990-12-11 | 1992-10-06 | Theratech, Inc. | Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels |
| US5164190A (en) * | 1990-12-11 | 1992-11-17 | Theratech, Inc. | Subsaturated transdermal drug delivery device exhibiting enhanced drug flux |
| AU664178B2 (en) * | 1991-03-19 | 1995-11-09 | Vithal J. Rajadhyaksha | Compositions and method comprising aminoalcohol derivatives as membrane penetration enhancers |
| US5352456A (en) * | 1991-10-10 | 1994-10-04 | Cygnus Therapeutic Systems | Device for administering drug transdermally which provides an initial pulse of drug |
| US5239714A (en) * | 1992-08-12 | 1993-08-31 | Huang Ming T | Playpen structure |
| JPH0679002A (ja) * | 1993-12-14 | 1994-03-22 | Hisamitsu Pharmaceut Co Inc | 経皮投与用パッチシステム |
| DE4310012A1 (de) * | 1993-03-27 | 1994-09-29 | Roehm Gmbh | Dermales therapeutisches System aus einer schmelzfähigen Poly(meth)acrylat-Mischung |
| HU223042B1 (hu) * | 1993-04-20 | 2004-03-01 | Hexal Ag. | Parkinson-kór kezelésére alkalmas hatóanyagot tartalmazó tapasz |
| US5762952A (en) * | 1993-04-27 | 1998-06-09 | Hercon Laboratories Corporation | Transdermal delivery of active drugs |
| US5613958A (en) * | 1993-05-12 | 1997-03-25 | Pp Holdings Inc. | Transdermal delivery systems for the modulated administration of drugs |
| US5554381A (en) * | 1993-08-09 | 1996-09-10 | Cygnus, Inc. | Low flux matrix system for delivering potent drugs transdermally |
| ATE183926T1 (de) * | 1993-09-29 | 1999-09-15 | Alza Corp | Hautpermeabilitaetserhöher bestehend aus monoglycerid/laktat estern |
| US5714162A (en) * | 1994-09-16 | 1998-02-03 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Scopolamine patch |
| US5635203A (en) * | 1994-09-29 | 1997-06-03 | Alza Corporation | Transdermal device having decreased delamination |
| US5505958A (en) * | 1994-10-31 | 1996-04-09 | Algos Pharmaceutical Corporation | Transdermal drug delivery device and method for its manufacture |
| AU695170B2 (en) * | 1994-12-21 | 1998-08-06 | Theratech, Inc. | Transdermal delivery system with adhesive overlay and peel seal disc |
| US5614210A (en) * | 1995-03-31 | 1997-03-25 | Minnesota Mining And Manufacturing Company | Transdermal device for the delivery of alfuzosin |
| US5882676A (en) * | 1995-05-26 | 1999-03-16 | Alza Corporation | Skin permeation enhancer compositions using acyl lactylates |
| US5693335A (en) * | 1995-06-07 | 1997-12-02 | Cygnus, Inc. | Skin permeation enhancer composition for use with sex steroids |
| US5785991A (en) * | 1995-06-07 | 1998-07-28 | Alza Corporation | Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate |
| US6093419A (en) * | 1995-06-07 | 2000-07-25 | Lectec Corporation | Compliance verification method and device in compulsory drug administration |
| DE19527925C2 (de) * | 1995-07-29 | 1997-07-03 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit einer trennmittelbeschichteten Schutzschicht |
| US5900198A (en) * | 1996-01-31 | 1999-05-04 | Hori; Yasunori | Method of producing molded resin product |
| JP3836566B2 (ja) * | 1996-05-13 | 2006-10-25 | 久光製薬株式会社 | フェンタニル含有経皮投与テープ製剤 |
| TW411277B (en) * | 1996-05-13 | 2000-11-11 | Hisamitsu Pharmaceutical Co | Percutaneous tape preparation containing fentanyl |
| US5985317A (en) * | 1996-09-06 | 1999-11-16 | Theratech, Inc. | Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents |
| US6004578A (en) * | 1996-10-24 | 1999-12-21 | Alza Corporation | Permeation enhances for transdermal drug delivery compositions, devices and methods |
| IT1286768B1 (it) | 1996-11-15 | 1998-07-17 | Alfredo Cecchini | Lettino da sole girevole |
| US5998911A (en) * | 1996-11-26 | 1999-12-07 | Ngk Insulators, Ltd. | Vibrator, vibratory gyroscope, and vibration adjusting method |
| DE19653606A1 (de) * | 1996-12-20 | 1998-06-25 | Roehm Gmbh | Haft- und Bindemittel aus (Meth)acrylatpolymer, organischer Säure und Weichmacher |
| DE19653605C2 (de) * | 1996-12-20 | 2002-11-28 | Roehm Gmbh | Haft- und Bindemittel für dermale oder transdermale Therapiesysteme und dessen Verwendung zur Herstellung eines transdermalen Therapiesystems |
| US6203817B1 (en) * | 1997-02-19 | 2001-03-20 | Alza Corporation | Reduction of skin reactions caused by transdermal drug delivery |
| KR20000075804A (ko) * | 1997-02-28 | 2000-12-26 | 스프레이그 로버트 월터 | 테스토스테론의 경피 전달 기구 |
| US7150881B2 (en) | 1997-06-26 | 2006-12-19 | Mylan Technologies, Inc. | Adhesive mixture for transdermal delivery of highly plasticizing drugs |
| GB9714650D0 (en) | 1997-07-11 | 1997-09-17 | Strakan Ltd | Block copolymer |
| US5948433A (en) * | 1997-08-21 | 1999-09-07 | Bertek, Inc. | Transdermal patch |
| IT1294748B1 (it) * | 1997-09-17 | 1999-04-12 | Permatec Tech Ag | Formulazione per un dispositivo transdermico |
| US6210705B1 (en) * | 1997-12-15 | 2001-04-03 | Noven Pharmaceuticals, Nc. | Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate |
| JP2002523144A (ja) * | 1998-08-20 | 2002-07-30 | スリーエム イノベイティブ プロパティズ カンパニー | 包帯への噴霧および薬物送達システム |
| DE60017831T3 (de) | 1999-01-14 | 2009-12-17 | Noven Pharmaceuticals, Inc., Miami | Dermale zusammensetzungen |
| EP1170004B1 (de) * | 1999-04-13 | 2010-10-27 | Hisamitsu Pharmaceutical Co., Inc. | Zubereitungen zur perkutanen absorption |
| KR20010036685A (ko) * | 1999-10-11 | 2001-05-07 | 김윤 | 펜타닐을 함유하는 매트릭스형 경피투여제 |
| US6164190A (en) * | 1999-12-16 | 2000-12-26 | Tien Lin; Yu Mei | Tea infusing device |
| US20020119187A1 (en) * | 2000-09-29 | 2002-08-29 | Cantor Adam S. | Composition for the transdermal delivery of fentanyl |
| DK1381352T3 (da) * | 2001-03-16 | 2007-07-09 | Alza Corp | Plaster til transdermal indgivelse af fentanyl |
| DE10141650C1 (de) * | 2001-08-24 | 2002-11-28 | Lohmann Therapie Syst Lts | Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen |
| DK1480625T3 (da) * | 2002-03-06 | 2008-10-27 | Hexal Ag | Transdermalt system med fentanyl |
| CA2496454A1 (en) * | 2002-04-23 | 2003-11-06 | Alza Corporation | Transdermal analgesic systems with reduced abuse potential |
| TWI296531B (en) * | 2002-10-18 | 2008-05-11 | Hisamitsu Pharmaceutical Co | Transdermal adhesive preparations for topical administration of fentanyl |
| DE10252725A1 (de) * | 2002-11-13 | 2004-06-03 | Lts Lohmann Therapie-Systeme Ag | Feuchtigkeitsaktivierbare Klebstoffe für medizinische Anwendungszwecke |
| CA2543610A1 (en) * | 2003-10-30 | 2005-05-19 | Alza Corporation | Transdermal analgesic systems having reduced abuse potential |
| JP4745747B2 (ja) * | 2004-08-12 | 2011-08-10 | 日東電工株式会社 | フェンタニル含有貼付製剤 |
| US8252328B2 (en) * | 2006-01-06 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
-
2001
- 2001-09-26 US US09/965,610 patent/US20020119187A1/en not_active Abandoned
- 2001-09-27 JP JP2002530047A patent/JP2004513890A/ja active Pending
- 2001-09-27 PT PT91763904T patent/PT2158905E/pt unknown
- 2001-09-27 AU AU2002215315A patent/AU2002215315C1/en not_active Expired
- 2001-09-27 IL IL15485701A patent/IL154857A0/xx unknown
- 2001-09-27 EP EP09176390A patent/EP2158905B1/de not_active Revoked
- 2001-09-27 EP EP10181393A patent/EP2266547A1/de not_active Withdrawn
- 2001-09-27 BR BR0114315-8A patent/BR0114315A/pt active Search and Examination
- 2001-09-27 ES ES09176390T patent/ES2407987T3/es not_active Expired - Lifetime
- 2001-09-27 PL PL01360708A patent/PL360708A1/xx not_active Application Discontinuation
- 2001-09-27 DE DE60140616T patent/DE60140616D1/de not_active Expired - Lifetime
- 2001-09-27 EP EP20090176388 patent/EP2153827A3/de not_active Ceased
- 2001-09-27 CZ CZ2003-890A patent/CZ305119B6/cs not_active IP Right Cessation
- 2001-09-27 EE EEP200300123A patent/EE05391B1/xx unknown
- 2001-09-27 MX MXPA03002548A patent/MXPA03002548A/es not_active Application Discontinuation
- 2001-09-27 HU HU0302926A patent/HUP0302926A3/hu unknown
- 2001-09-27 AT AT01983925T patent/ATE449599T1/de active
- 2001-09-27 ES ES09176398.7T patent/ES2621169T3/es not_active Expired - Lifetime
- 2001-09-27 WO PCT/US2001/031052 patent/WO2002026217A2/en active IP Right Grant
- 2001-09-27 EP EP01983925A patent/EP1322299B1/de not_active Expired - Lifetime
- 2001-09-27 NZ NZ524767A patent/NZ524767A/xx not_active IP Right Cessation
- 2001-09-27 DK DK09176398.7T patent/DK2153828T3/en active
- 2001-09-27 CN CNB018164722A patent/CN100490805C/zh not_active Expired - Lifetime
- 2001-09-27 CA CA002423836A patent/CA2423836C/en not_active Expired - Lifetime
- 2001-09-27 PT PT91763987T patent/PT2153828T/pt unknown
- 2001-09-27 EP EP09176398.7A patent/EP2153828B1/de not_active Revoked
- 2001-09-27 EP EP20090176378 patent/EP2158904A3/de not_active Withdrawn
- 2001-09-27 AU AU1531502A patent/AU1531502A/xx active Pending
- 2001-09-27 KR KR10-2003-7004485A patent/KR20030043978A/ko not_active Application Discontinuation
- 2001-09-27 DK DK09176390.4T patent/DK2158905T3/da active
- 2001-10-01 AR ARP010104619A patent/AR037081A1/es not_active Application Discontinuation
-
2003
- 2003-03-13 NO NO20031165A patent/NO333525B1/no not_active IP Right Cessation
-
2006
- 2006-06-15 US US11/424,448 patent/US20060222691A1/en not_active Abandoned
-
2009
- 2009-05-11 JP JP2009115044A patent/JP4976445B2/ja not_active Expired - Lifetime
-
2010
- 2010-01-27 JP JP2010015817A patent/JP2010100650A/ja not_active Withdrawn
- 2010-06-22 US US12/820,280 patent/US20100255073A1/en not_active Abandoned
- 2010-08-06 US US12/851,808 patent/US20110038918A1/en not_active Abandoned
- 2010-12-15 JP JP2010279739A patent/JP5425751B2/ja not_active Expired - Lifetime
-
2011
- 2011-10-18 US US13/275,498 patent/US20120269878A2/en not_active Abandoned
-
2012
- 2012-11-08 US US13/672,057 patent/US20130064877A1/en not_active Abandoned
-
2013
- 2013-07-09 US US13/937,365 patent/US20130295158A1/en not_active Abandoned
- 2013-09-26 JP JP2013200504A patent/JP2013256536A/ja not_active Withdrawn
-
2014
- 2014-02-25 US US14/188,909 patent/US20140170206A1/en not_active Abandoned
- 2014-10-07 US US14/507,981 patent/US20150025480A1/en not_active Abandoned
-
2015
- 2015-07-15 US US14/799,774 patent/US20150313851A1/en not_active Abandoned
- 2015-12-18 JP JP2015247296A patent/JP6437908B2/ja not_active Expired - Lifetime
-
2016
- 2016-03-09 US US15/064,877 patent/US20160184235A1/en not_active Abandoned
- 2016-10-20 US US15/298,891 patent/US20170035704A1/en not_active Abandoned
-
2017
- 2017-03-24 CY CY20171100368T patent/CY1118798T1/el unknown
- 2017-06-30 US US15/638,576 patent/US20170296486A1/en not_active Abandoned
-
2018
- 2018-01-26 US US15/880,784 patent/US20180153823A1/en not_active Abandoned
-
2019
- 2019-02-08 US US16/270,808 patent/US20190167603A1/en not_active Abandoned
- 2019-09-06 US US16/562,710 patent/US20200000739A1/en not_active Abandoned
-
2020
- 2020-04-29 US US16/861,872 patent/US20200253887A1/en not_active Abandoned
-
2021
- 2021-09-23 US US17/482,871 patent/US20220008352A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996008229A2 (en) * | 1994-09-14 | 1996-03-21 | Minnesota Mining And Manufacturing Company | Matrix for transdermal drug delivery |
Non-Patent Citations (1)
| Title |
|---|
| ROY, Samir D., Controlled transdermal delivery of fentanyl: Characterizations of pressure-sensitive adhesives for matrix patch design, Journal of Pharmaceutical Sciences, Volume 85, Issue 5, pages 491¿495, May 1996., Dated: 01.01.0001 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO333525B1 (no) | Preparat for transdermal levering av fentanyl | |
| AU2002215315A1 (en) | Composition for the transdermal delivery of fentanyl | |
| AU2007205756B2 (en) | Composition for the transdermal delivery of fentanyl |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: KINDEVA DRUG DELIVERY L.P., US |
|
| CREP | Change of representative | ||
| MK1K | Patent expired |